-
Yifan Pharmaceutical Receives NMPA Approval for Hyruan ONE in Knee Osteoarthritis Treatment
•
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced receiving market approval from the National Medical Products Administration (NMPA) for its in-licensed Category 5.1 drug Hyruan ONE (sodium hyaluronate), which is indicated for use in knee osteoarthritis. Hyruan ONE: A Single-Dose Preparation for Knee OsteoarthritisHyruan ONE, originally developed by LG…
-
Junshi Biosciences Challenges Alynlam’s PCSK9 siRNA Patent with CNIPA
•
Junshi Biosciences (SHA: 688180) is reportedly taking steps to challenge a key patent held by Alynlam Pharmaceutical related to the development of PCSK9-targeted small-interfering RNA (siRNA) therapies, such as the lipid-lowering drug Leqvio (inclisiran), which is now marketed globally by Novartis. CNIPA Oral Proceedings and Patent DisputeAccording to a notification…
-
ApolloBio Partners with Baidu Health to Enhance Marketing of IgM Nano Immunoglobulin Spray
•
Guangzhou-based biotech ApolloBio has signed a strategic cooperation agreement with Baidu Health. Under this partnership, Baidu will provide innovative digital support to enhance ApolloBio’s marketing activities, particularly for protective products related to infectious respiratory diseases. This includes an IgM nano immunoglobulin protective spray, known as a ‘liquid mask’ type nasal…
-
Yantai Dongcheng Pharmaceutical Gets Singapore Regulatory Approval for 177Lu-LNC1004 Phase I Study
•
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving the green light from the regulatory body in Singapore to initiate a Phase I clinical study for its radiotherapeutic drug, 177Lu-LNC1004, which targets fibroblast activation protein (FAP) and is under development to treat FAP-positive advanced solid tumors. This…
-
AcoStream Second-Generation Receives NMPA Marketing Approval for Peripheral Vascular Use
•
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its second-generation AcoStream, a product designed to remove blood clots in the peripheral vascular system. Advancement in Blood Clot Removal TechnologyThe first-generation version of AcoStream was approved for marketing in…
-
Shenzhen Kangtai Biological Partners with Biotis for 13-Valent Pneumococcal Vaccine in Indonesia
•
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has struck a partnership with Indonesian firm Biotis concerning a dual carrier 13-valent pneumococcal polysaccharide conjugate vaccine. This collaboration aims to enhance vaccine accessibility and public health initiatives in Indonesia. Agreement Details and Technical CollaborationAs per the agreement, Kangtai Bio will…
-
Harbour BioMed and AstraZeneca Partner to Advance Pharmaceutical Innovation in Yangtze River Delta
•
Harbour BioMed (HKG: 2142), a biotech with operations in the United States, the Netherlands, and Suzhou (China), has announced a partnership with UK major AstraZeneca (AZ, NASDAQ: AZN). The collaboration aims to advance the construction of a pharmaceutical industry innovation alliance in the Yangtze River Delta region, strengthen global collaboration…
-
Shuwen Biotech’s Subsidiary Signs Promotion Agreement with Sysmex Europe for Breast Cancer Detection Product
•
China-based diagnostic specialist Shuwen Biotech Co., Ltd announced that its wholly-owned German subsidiary, Cerca Biotech GmbH, has entered into a promotion agreement with Japanese firm Sysmex Corporation’s German unit, Sysmex Europe SE. Under the terms of the deal, Sysmex will promote and distribute Cerca’s MammaTyper, a breast cancer detection product…
-
Vcanbio Receives CDE Approval for VUM02 Clinical Trial in Idiopathic Pulmonary Fibrosis
•
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced receiving clinical trial approval from the Center for Drug Evaluation (CDE) for its VUM02 (human umbilical cord-derived mesenchymal stem cells), a Category 1 therapeutic biologic product. The therapy is set to be assessed as a treatment for idiopathic…
-
Luye Pharma Group Partners with Duopharma for Exclusive Marketing Rights of TCM in Malaysia
•
China-based Luye Pharma Group (HKG: 2186) has signed an agreement with Malaysia’s Duopharma Marketing Sdn Bhd, a subsidiary of Duopharma Biotech Berhad, to hand over exclusive marketing and distribution rights for a cholesterol management product in Malaysia. The product, developed in-house by Luye, is a traditional Chinese medicine (TCM) made…
-
Scorpion Therapeutics and Pierre Fabre Collaborate on NSCLC Therapies STX-721 and STX-241
•
US-based Scorpion Therapeutics Inc. has formed a collaboration and license deal with France-based Pierre Fabre, focusing on the co-development of Scorpion’s two potential therapies for non-small cell lung cancer (NSCLC), STX-721 and STX-241. Under the agreement, Pierre Fabre will be granted exclusive development and commercialization rights to these molecules in…
-
Sanofi Partners with Shenzhen’s Pingshan District to Boost Innovative Vaccines in China
•
French pharmaceutical major Sanofi (NASDAQ: SNY) has signed a partnership agreement with the Pingshan district government in Shenzhen, aiming to accelerate the introduction of innovative vaccines to the Chinese market and to foster the innovative development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA). Shenzhen’s Focus…
-
Haisco Pharmaceutical Gets CDE Approval for HSK38008 Prostate Cancer Clinical Study
•
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving approval from the Center for Drug Evaluation (CDE) to conduct a clinical study for its Category 1 chemical drug, HSK38008 oral preparation, in the treatment of prostate cancer. HSK38008: An Androgen Mutant AR-V7 Oral Degradation AgentHSK38008 is an androgen mutant…
-
Yiling Pharmaceutical’s G201-Na Receives CDE Approval for Phase Ia Study in Prostate Cancer Treatment
•
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced receiving approval from the Center for Drug Evaluation (CDE) to conduct a single-center, randomized, double-blind, placebo-controlled, dosage escalation Phase Ia study. The study will assess the safety, tolerability, and pharmacokinetics of G201-Na in healthy adult males in China. G201-Na: A Small…
-
Mabwell’s 9MW2821 ADC Shows Positive Signals in Solid Tumor Clinical Data
•
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced preliminary clinical data for its antibody-drug conjugate (ADC) 9MW2821, which targets Nectin-4. The data demonstrated positive therapeutic signals in multiple solid tumors and exhibited a good safety profile at the recommended Phase II dosage (RP2D). Mechanism of Action and Pharmaceutical…
-
Gates Foundation and NSFC Launch Partnership to Boost Regulatory Science in Vaccine Development
•
The Bill & Melinda Gates Foundation (Gates Foundation) and the National Natural Science Foundation of China (NSFC) have unveiled a strategic partnership aimed at enhancing regulatory science, with a particular focus on vaccine development. This joint program will invite research proposals centered on new regulatory science systems, tools, and methodologies,…
-
AffaMed Digital Initiates Clinical Study for AMD201 at Beijing Tiantan Hospital
•
AffaMed Digital, a company wholly owned by AffaMed Technologies—a joint venture between AffaMed Therapeutics and SIFI S.p.A.—has announced the first patient enrollment in a clinical study for its AMD201 at the Beijing Tiantan Hospital. This marks a significant step in the development of digital therapies for post-stroke cognitive impairment (PSCI).…
-
Corxel Pharmaceuticals’ OC-01 Nasal Spray Approved as Urgently Needed Drug in Hainan
•
Shanghai-based Corxel Pharmaceuticals (CORXEL), supported by RTW Investments, has announced that its OC-01 (varenicline) nasal spray has been approved by the Hainan Medical Products Administration as a clinically urgently needed import drug in Bo’ao Super Hospital. This marks a significant milestone as the product is the world’s first and only…
-
Harbour BioMed’s Nona Biosciences Partners with ExeVir Bio to Explore Infectious Disease Sector
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic partnership with Belgium-based ExeVir Bio. The collaboration aims to explore the infectious disease sector, with no financial details or other specifics disclosed at this time. ExeVir Bio’s Nanoantibody-Based Therapy PlatformExeVir Bio is a clinical biotechnology…
-
AbbVie’s China General Manager Ou Silang Steps Down, Intercon’s Colzi to Take Interim Role
•
Ou Silang, Vice President and China General Manager of US pharmaceutical major AbbVie (NYSE: ABBV), has decided to leave his post, according to an internal email. Intercon’s Senior Vice President Alberto Colzi will step in to take over temporarily until a successor is appointed. Ou Silang’s Tenure and BackgroundOu Silang…
